Data Vantage | ABM Respiratory Care, Chitose Bio Evolution, others in focus
Edition #411, 01 October 2024
Share As a free subscriber, you’re reading a redacted version of DealStreetAsia’s premium DATA VANTAGE twice-weekly newsletter. Unlock access to the complete version by picking up any of our premium subscription plans.
Dear Reader,
Respiratory care solutions provider ABM Respiratory Care has received additional investments worth $5.6 million as part of a Series B round from Worthy Ventures Resources, TAH Ventures, and other individual investors.
The latest round has raised the company’s total funding to date to over $19 million.
The company had secured around $4.1 million earlier this month from Advanced Medtech Holdings and SEEDS Capital, among other investors. This brings the total capital raised in the Series B round to $9.7 million.
Founded in 2017 and having a presence in India, Singapore, and the US, the company develops advanced respiratory therapy devices that use automation and smart technology to help manage and treat chronic and acute respiratory conditions.
Gender diversity in SE Asian venture firms almost unchanged from last year
Women accounted for only 17.9% of decision-makers among Southeast Asia-based venture investors, according to the Women in SE Asia’s VC Ecosystem 2024 report, which analysed over 330 active venture investors including venture capital firms, venture debt providers, accelerators, and incubators headquartered in the region. The proportion of female investment decision-makers has remained stagnant since 2023 (17.4%).
While the number of female decision-makers in the region increased by 16.3% from last year, male representation grew by 12%.
The Philippines and Thailand topped in terms of the share of female cheque writers at local venture firms, while Malaysia came last.
The data and information in this newsletter comes from DATA VANTAGE, which tracks regulatory filings to provide you with the latest information on startup fundraising, shareholding and financials. Find out how it can aid you in your decision-making — book a demo today or write to us at subs@dealstreetasia.com
Schedule a free demo session now Executives at top investment firms, financial services majors, and leading private companies use DATA VANTAGE to make smarter investment decisions in Asia. (See how)
Other updates from DATA VANTAGE
Singapore-based integrated healthcare services provider Fullerton Healthcare allotted ordinary shares worth [Redacted] last week to its parent Fullerton Health Corp.
Singapore-based biotech company Chitose Bio Evolution received [Redacted] last week from [Redacted] and [Redacted].
Singapore-headquartered Juniper Biologics saw its profits surge over [Redacted] in the financial year ended December 31, 2023, while it witnessed a roughly [Redacted] increase in revenue during the same period.
xto10x, an India-based business consulting firm that helps startups scale up, bagged $1.7 million last week from 3STATE Ventures.
Singapore- and US-based AI-powered climate risk analysis platform AlphaGeo (formerly Climate Alpha) secured [Redacted] last week from [Redacted].
SynPhNe, a Singapore-based provider of wearable solutions for neurorehabilitation, saw its losses increase nearly [Redacted] in the financial year ended December 31, 2023, despite a [Redacted] rise in revenue during the period.
Singapore-based healthtech firm NDR Medical has acquired 1,725 ordinary shares from one of its shareholders, Microport Interbot Limited.
As a free subscriber, you’re reading a redacted version of DealStreetAsia’s premium DATA VANTAGE twice-weekly newsletter. Unlock access to the complete version by picking up any of our premium subscription plans. Anticipate Asia’s Rising Stars and Secure Lucrative Exits
To keep pace with today’s constantly evolving markets, data must be smarter, deeper, and instantly accessible. DATA VANTAGE is our smart, continuously updated research & analytics platform featuring:
- Key financials, fundraising data, and shareholding information for over 3,000 Asian venture-backed companies registered in Singapore and Indonesia
- Up to 3 new research reports per month
- Monthly and quarterly data on private funding in SE Asia, India, and Greater China
- Twice-weekly DATA VANTAGE premium newsletter
- Alerts for monitoring companies and sectors
- 50% discount on tickets to our flagship summit
- Full access to DealStreetAsia’s premium stories and archives
Combine editorial insights with robust data & research. Gain a competitive edge in the ever-changing private capital investment landscape.
>> Curious? Book a demo now to explore our database!<< © DEALSTREETASIA 2014–2024.
